Biomarker Panel for Early Sinusoidal Obstruction Syndrome Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for diagnosing sinusoidal obstruction syndrome (SOS) after hematopoietic stem cell transplantation lack non-invasive and accurate biomarkers, leading to delayed diagnosis and increased mortality, as existing clinical criteria are late indicators and invasive tests pose risks.

Innovation Solution

A biomarker panel comprising ST2, ANG2, L-Ficolin, hyaluronic acid (HA), and VCAM1 is used to diagnose and prognose SOS by measuring their expression levels in biological samples, enabling early detection and preemptive intervention.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If clinical criteria (Baltimore and Seattle scales) and ultrasound examination are used to diagnose SOS, then diagnosis can be made, but these are late indicators that delay early detection and treatment

Engineering Contradiction:

Improvediagnosis timing accuracyVSAvoidtime to diagnosis

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent applies preliminary action by measuring biomarker expression levels (ST2, ANG2, L-Ficolin, HA, VCAM1) in biological samples obtained early after HSCT (within first week), before clinical symptoms manifest. This allows prediction of SOS risk and early intervention, resolving the contradiction by enabling diagnosis before traditional late indicators appear.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If liver biopsy is performed to confirm SOS diagnosis, then definitive diagnosis can be obtained, but patients face increased risk for bleeding complications

Engineering Contradiction:

Improvediagnosis accuracyVSAvoidbleeding risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses biomarker panels (ST2, ANG2, L-Ficolin, HA, VCAM1) as intermediary substances that provide diagnostic information without requiring invasive procedures. These biomarkers serve as mediators between the disease state and diagnosis, allowing accurate assessment of SOS risk and severity while avoiding the bleeding risks associated with liver biopsy.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If traditional diagnostic methods are used, then diagnosis can be made, but mortality remains high due to delayed intervention

Engineering Contradiction:

Improvepatient survival rateVSAvoidtime to intervention

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent enables preliminary action by identifying SOS risk through biomarker measurement in the first week after HSCT, allowing preemptive intervention before severe disease develops. This resolves the contradiction by providing both early detection (reducing time loss) and accurate risk stratification (improving reliability of survival outcomes).

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent implements feedback by continuously monitoring biomarker expression levels to assess SOS risk and disease progression. This allows dynamic adjustment of clinical management and timely intervention based on actual patient status, improving survival outcomes while optimizing the timing of interventions.

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS11193945B2Methods for detecting sinusoidal obstructive syndrome (SOS)

Publication Date: 2021.12.07 INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP

AI summary

Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.